

CITATION REPORT

List of articles citing

The Impact of Tamsulosin Oral Controlled Absorption System (OCAS) on Nocturia and the Quality of Sleep: Preliminary Results of a Pilot Study

DOI: 10.1016/j.eursup.2004.12.001
European Urology Supplements, 2005, 4, 61-68.

Source: <https://exaly.com/paper-pdf/39130991/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
64	Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists. <i>BJU International</i> , 2005 , 95 Suppl 4, 29-36	5.6	96
63	The Development of the Oral Controlled Absorption System (OCAS [®]): A New Improved Formulation of Tamsulosin. <i>European Urology Supplements</i> , 2005 , 4, 1-4	0.9	7
62	The Underestimated Impact of Nocturia on Quality of Life. <i>European Urology Supplements</i> , 2005 , 4, 17-19	0.9	20
61	Night Time Symptom Control with Omnic (Tamsulosin) Oral Controlled Absorption System (OCAS [®]). <i>European Urology Supplements</i> , 2005 , 4, 14-16	0.9	7
60	The Oral Controlled Absorption System (OCAS [®]): The Evolution of Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH). <i>European Urology Supplements</i> , 2005 , 4, 20-22	0.9	1
59	Behaviour and transit of tamsulosin Oral Controlled Absorption System in the gastrointestinal tract. <i>Current Medical Research and Opinion</i> , 2006 , 22, 2323-8	2.5	16
58	Tamsulosin \square modified-release and oral-controlled absorption system formulations in the treatment of benign prostatic hyperplasia. <i>Therapy: Open Access in Clinical Medicine</i> , 2006 , 3, 237-246		7
57	Future Directions in Evaluating Nocturia and Its Impact in Patients with LUTS/BPH. <i>European Urology Supplements</i> , 2006 , 5, 19-21	0.9	0
56	The Impact of Nocturia in Patients with LUTS/BPH: Need for New Recommendations. <i>European Urology Supplements</i> , 2006 , 5, 12-18	0.9	21
55	The Measurement of Nocturia and Its Impact on Quality of Sleep and Quality of Life in LUTS/BPH. <i>European Urology Supplements</i> , 2006 , 5, 3-11	0.9	16
54	Introduction and summary. <i>BJU International</i> , 2006 , 98, 1-2	5.6	54
53	LUTS/BPH in clinical practice: the importance of nocturia and quality of sleep. <i>BJU International</i> , 2006 , 98, 3-8	5.6	11
52	Pharmacokinetic profile of tamsulosin OCAS. <i>BJU International</i> , 2006 , 98, 9-12	5.6	4
51	Efficacy and safety of tamsulosin OCAS. <i>BJU International</i> , 2006 , 98, 13-17	5.6	13
50	Predictors of nocturia quality of life before and shortly after prostatectomy. <i>Urology</i> , 2007 , 70, 493-7	1.6	40
49	Introduction and Conclusions. <i>European Urology Supplements</i> , 2007 , 6, 573-575	0.9	3
48	Impact of Tamsulosin OCAS on Energy of Patients with LUTS/BPH. <i>European Urology Supplements</i> , 2007 , 6, 594-599	0.9	

47	Impact of Nocturia on Sleep and Energy. <i>European Urology Supplements</i> , 2007 , 6, 585-593	0.9	9
46	Evaluation of Quality of Life and Quality of Sleep in Clinical Practice. <i>European Urology Supplements</i> , 2007 , 6, 576-584	0.9	11
45	Nocturia and Tamsulosin OCAS. <i>European Urology Supplements</i> , 2007 , 6, 723-727	0.9	4
44	[Importance of nocturia and its impact on quality of sleep and quality of life in patient with benign prostatic hyperplasia]. <i>Actas Urológicas Españolas</i> , 2007 , 31, 262-9	0.7	11
43	Tamsulosin MR and OCAS (modified release and oral controlled absorption system): current therapeutic uses. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 813-24	4	4
42	Tamsulosin modified release and oral controlled absorption system in the management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008 , 4, 771-82	5.5	2
41	Desmopressin for the treatment of adult nocturia. <i>Therapy: Open Access in Clinical Medicine</i> , 2008 , 5, 667-683		9
40	Nocturia: a non-specific but important symptom of urological disease. <i>International Journal of Urology</i> , 2009 , 16, 249-56	2.3	39
39	Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction. <i>World Journal of Urology</i> , 2010 , 28, 3-8	4	25
38	Effectiveness of tamsulosin hydrochloride and its mechanism in improving nocturia associated with lower urinary tract symptoms/benign prostatic hyperplasia. <i>Neurourology and Urodynamics</i> , 2010 , 29, 1276-81	2.3	18
37	Nocturia research: current status and future perspectives. <i>Neurourology and Urodynamics</i> , 2010 , 29, 623-83		31
36	Thinking beyond the bladder: antidiuretic treatment of nocturia. <i>International Journal of Clinical Practice</i> , 2010 , 64, 807-16	2.9	36
35	The role of nocturia in the quality of life of men with lower urinary tract symptoms. <i>BJU International</i> , 2010 , 105, 1141-6	5.6	42
34	The role of nocturia in the quality of life of men with lower urinary tract symptoms. <i>BJU International</i> , 2010 , 105, 1016-7; author reply 1017-8	5.6	4
33	Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations. <i>Clinical Pharmacokinetics</i> , 2010 , 49, 177-88	6.2	37
32	Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. <i>Journal of Urology</i> , 2011 , 186, 170-4	2.5	36
31	Tamsulosin versus transurethral resection of the prostate: effect on nocturia as a result of benign prostatic hyperplasia. <i>International Journal of Urology</i> , 2011 , 18, 243-8	2.3	26
30	The effect of robot-assisted laparoscopic prostatectomy on nocturia. <i>Journal of Endourology</i> , 2012 , 26, 861-5	2.7	4

29	A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management--a systematic review and meta-analysis. <i>European Urology</i> , 2012 , 62, 877-90	10.2	173
28	Preparation and in vivo evaluation of spray dried matrix type controlled-release microparticles of tamsulosin hydrochloride for orally disintegrating tablet. <i>Drug Development and Industrial Pharmacy</i> , 2012 , 38, 1179-87	3.6	5
27	Pharmacoscintigraphy confirms consistent tamsulosin release from a novel triple-layered tablet. <i>International Journal of Pharmaceutics</i> , 2013 , 454, 41-6	6.5	5
26	Focus on nocturia in the elderly. <i>Aging Health</i> , 2013 , 9, 389-402		1
25	Current pharmacotherapy of nocturia. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 885-94	4	4
24	Nocturia: current concepts and future perspectives. <i>Acta Physiologica</i> , 2013 , 207, 53-65	5.6	12
23	Current evaluation and treatment of nocturia. <i>Korean Journal of Urology</i> , 2013 , 54, 492-8		14
22	Nocturia in the Elderly. <i>Current Bladder Dysfunction Reports</i> , 2014 , 9, 364-371	0.4	
21	Management of nocturia: the role of antidiuretic pharmacotherapy. <i>Neurourology and Urodynamics</i> , 2014 , 33 Suppl 1, S19-24	2.3	16
20	Nocturia improvement in the combination of Avodart(®) and tamsulosin (CombAT) study. <i>World Journal of Urology</i> , 2014 , 32, 1133-40	4	13
19	Once-daily oxybutynin patch improves nocturia and sleep quality in Japanese patients with overactive bladder: Post-hoc analysis of a phase III randomized clinical trial. <i>International Journal of Urology</i> , 2015 , 22, 684-8	2.3	8
18	Delay of first voiding episode is associated with longer reported sleep duration. <i>Sleep Health</i> , 2015 , 1, 211-213	4	7
17	Delaying time to first nocturnal void may have beneficial effects on reducing blood glucose levels. <i>Endocrine</i> , 2016 , 53, 722-9	4	8
16	Pitfalls and opportunities in multidisciplinary research about nocturia in adults. <i>Acta Clinica Belgica</i> , 2017 , 72, 2-5	1.8	3
15	Desmopressin acetate nasal spray for adults with nocturia. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 1281-1293	3.8	10
14	Medical Treatment of Nocturia in Men with Lower Urinary Tract Symptoms: Systematic Review by the European Association of Urology Guidelines Panel for Male Lower Urinary Tract Symptoms. <i>European Urology</i> , 2017 , 72, 757-769	10.2	42
13	Management Strategies for Nocturia. <i>Current Urology Reports</i> , 2019 , 20, 75	2.9	3
12	The discrepancy between European Association of Urology (EAU) guidelines and daily practice in the evaluation and management of nocturia: results of a Dutch survey. <i>World Journal of Urology</i> , 2019 , 37, 2517-2522	4	2

11	Management and treatment. 2020 , 71-106		
10	Factors Associated With Nocturia-Related Quality of Life in Men With Lower Urinary Tract Symptoms and Treated With Tamsulosin Oral Controlled Absorption System in a Non-Interventional Study. <i>Frontiers in Pharmacology</i> , 2020 , 11, 816	5.6	4
9	Pharmacologic management of nocturnal polyuria: a contemporary assessment of efficacy, safety, and progress toward individualized treatment. <i>Therapeutic Advances in Urology</i> , 2021 , 13, 1756287220988438	3.2	5
8	Nocturia and Surgical Treatment of the Prostate. 2012 , 115-126		1
7	Nocturia: current status and future perspectives. <i>Current Opinion in Obstetrics and Gynecology</i> , 2011 , 23, 376-85	2.4	17
6	Tamsulosin - modified-release and oral-controlled absorption system formulations in the treatment of benign prostatic hyperplasia. <i>Therapy: Open Access in Clinical Medicine</i> , 2006 , 3, 237-246		2
5	Lower Urinary Tract Pharmacotherapy for Nocturia. 2012 , 127-134		1
4	Pharmacotherapy for Nocturia. 2019 , 163-176		
3	DataSheet_1.docx. 2020 ,		
2	DataSheet_2.docx. 2020 ,		
1	A rude awakening: management of nocturia in men. 2022 , 13, 24-28		0